Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
e<br />
EBV see Epstein-Barr virus<br />
EDR see escalating doses regimen<br />
EGF see epidermal growth factor<br />
ELISPOT 195<br />
embryonic antigens 231<br />
endosome, PRR receptors 271f.<br />
endotoxin, bacterial immunotherapy 269<br />
eosinophils, tumor cell killing 218<br />
Ep-CAM/KS antigen (KSA) 312±329, 341<br />
epidermal growth factor (EGF) receptor 347,<br />
354, 365f.<br />
epitope deduction 6ff.<br />
epitope linkage 233<br />
epitope spreading 214, 222<br />
epitopes<br />
±, CTL 32, 34±37, 41±44<br />
±, definition 223<br />
±, multiple peptide 187<br />
±, near-self 209, 211<br />
±, subdominant 211, 224<br />
±, T cell 3±16<br />
±, tumor antigen-associated 220<br />
±, tumor-associated T cell 231ff.<br />
Epstein-Barr virus (EBV), IL-10 homologs 157<br />
ER retention motif, gp96 262<br />
erbB familiy, oncogenic receptors 290ff.<br />
erbB2 receptor 347, 354, 360f., 368<br />
escalating doses regimen (EDR) 303<br />
Escherichia coli, immunotoxins 351f.<br />
evolutionary tuning, of the immunoresponse<br />
206±209<br />
exosomes, dendritic cells 180<br />
exotoxin, pseudomonas see pseudomonas<br />
exotoxin<br />
expression<br />
±, hTERT 8<br />
±, IL-10 155f., 161±164<br />
±, of HSPs 261f.<br />
±, see also gene expression<br />
f<br />
FACS see fluorescence-activated cell sorting<br />
FAP see Fas-associated phosphatase<br />
Fas-associated phosphatase (FAP) 111<br />
Fas-FasL Pathway 110ff.<br />
±, see also CD95-CD95 (CD95L) lig<strong>and</strong> pathway<br />
FasL see Fas-FasL Pathway<br />
FBP see folate binding protein<br />
Fc receptors (FcRs) 277<br />
±, g 102<br />
±, T-body approach 288<br />
FcRs see Fc receptors<br />
fever, modulation of HSPs 261<br />
Index<br />
FGF see fibroblast growth factor<br />
fibroblast growth factor (FGF), immunotoxins<br />
350<br />
first-generation immunotoxins 349f.<br />
flow cytometry detection of cytokine-producing<br />
cells 195<br />
Flt-3L, dendritic cells 195<br />
fluorescence-activated cell sorting (FACS) 64<br />
folate binding protein(FBP)-specific CR 292ff.<br />
foreign antigens 211<br />
±, definition 224<br />
foscarnet 305<br />
Freund's adjuvant, incomplete 234<br />
fusion proteins<br />
±, antibody-cytokine 311f.<br />
±, ch14.18-IL-2 330±341<br />
±, HSP/peptide 260<br />
±, lymphotoxin (LT)-a 313<br />
fusion technology, HCV 236f.<br />
Fv see variable region fragment<br />
g<br />
galactose-specific lectins, immunotoxins<br />
351<br />
gancyclovir (GCV) 304ff.<br />
gangliosides<br />
± , GD2 312f., 330ff., 341<br />
±, RCC-derived 100<br />
±, tumor-associated 109<br />
±, tumor-derived 105<br />
gastro-intestinal cancer, clinical trials 191<br />
GCV see gancyclovir<br />
GD 2 see disialoganglioside<br />
gene expression 10, 18f.<br />
±, MHC antigens 63f.<br />
±, underexpressed genes 23<br />
±, see also expression<br />
genetic linkages to autoimmune diseases<br />
215f.<br />
genomics, cancer 10<br />
glioma<br />
±, clinical trials 191<br />
±, HCV 239<br />
Glucksberg grade, GvHD 300<br />
glycoproteins, immunotoxins 351<br />
GM-CSF see granulocyte macrophage colony<br />
stimulating factor<br />
gp70 envelope protein 316<br />
gp96, HSPs 253ff., 258±263<br />
gp100 antigen 334f.<br />
graft-versus-host (GvH) reactions 299±307<br />
graft-versus-host disease (GvHD) 299±307<br />
±, leukemia 361f.<br />
graft-versus-leukemia (GvL) effect 301ff.<br />
399
Change language